Read this manager's filing book
Disclosed positions
Foresite Capital Management VI LLC: source evidence dated 2026-08-15T03:59:59.999Z.
- Issuer
- CG Oncology, Inc.
- Ticker
- CGON
- Class
- COM
- Reported value
- $168,358,233
- Reported amount
- 2,369,574
- Unit
- SH
- Option
- None
The displayed owner or issuer and source fields identify the receipt to verify; keep reporting and availability dates separate.
What was reported for this quarter?
13F positions are dated quarter-end holdings, with later publication and possible amendments. Read report period and availability before calling them current.
SEC 13F-HR: 0001104659-26-097133Open the effective filing receipt and inspect shares, value and any put/call classification separately.
Browse institutional filings
Open the effective filing receipt and inspect shares, value and any put/call classification separately.
Browse institutional filingsKeep reporting dates and units beside the answer, and inspect its original citations.
Disclosed positions
See the complete disclosed positions
| CG Oncology, Inc. | CGON | COM | $168,358,233 | 2,369,574 | SH | None |
| ALUMIS INC. | ALMS | COM | $119,529,434 | 4,247,670 | SH | None |
| Seaport Therapeutics, Inc. | SPTX | COM | $38,651,196 | 1,779,521 | SH | None |
| Denali Therapeutics Inc. | DNLI | COM | $35,924,950 | 1,396,771 | SH | None |
| Celldex Therapeutics, Inc. | CLDX | COM | $32,734,121 | 879,713 | SH | None |
| AGIOS PHARMACEUTICALS, INC. | AGIO | COM | $29,131,350 | 785,000 | SH | None |
| Corvus Pharmaceuticals, Inc. | CRVS | COM | $27,358,621 | 1,831,233 | SH | None |
| Parabilis Medicines, Inc. | PBLS | COM | $27,343,834 | 999,044 | SH | None |
| GH Research PLC | GHRS | ORD | $25,280,452 | 940,493 | SH | None |
| Jade Biosciences, Inc. | JBIO | COM | $19,701,741 | 886,667 | SH | None |
| Hinge Health, Inc. | HNGE | CL A | $18,293,200 | 220,400 | SH | None |
| Kymera Therapeutics, Inc. | KYMR | COM | $16,779,890 | 146,332 | SH | None |
| AtaiBeckley Inc. | ATAI | COM | $14,492,500 | 2,750,000 | SH | None |
| Verastem, Inc. | VSTM | COM | $12,020,130 | 3,146,631 | SH | None |
| Beam Therapeutics Inc. | BEAM | COM | $11,325,600 | 330,000 | SH | None |
| Minerva Neurosciences, Inc. | NERV | COM | $11,019,991 | 1,985,584 | SH | None |
| ArriVent BioPharma, Inc. | AVBP | COM | $10,468,586 | 301,341 | SH | None |
| Aura Biosciences, Inc. | AURA | COM | $9,466,671 | 1,333,334 | SH | None |
| Crinetics Pharmaceuticals, Inc. | CRNX | COM | $7,933,414 | 212,010 | SH | None |
| Research Alliance Corp III | Unresolved | CL A | $3,210,000 | 300,000 | SH | None |
| Zura Bio Ltd | ZURA | CL A | $2,655,000 | 450,000 | SH | None |
| Kailera Therapeutics, Inc. | KLRA | COM | $826,125 | 37,500 | SH | None |
| Disc Medicine, Inc. | IRON | COM | $70,946 | 970 | SH | None |
No matching rows. Clear the filter to see all records.
Largest 50 positions by reported value; the filing may contain more positions.
How amendments affect these holdings
This view uses 1 effective filing version(s). A restatement replaces the previous book; a new-holdings amendment adds positions. 1 positions lack a resolved ticker and 0 positions are put or call entries.
A 13F is a delayed quarterly snapshot of disclosed holdings. It is not a complete trade ledger and does not reveal every position in a manager's portfolio. Option values refer to the reported underlying position rather than a traded option premium.
Quarter end and public filing date
Use the filing's public availability date when constructing a historical observation. The quarter-end report period is earlier and cannot be substituted for when the public learned the holdings.